- Home
- KLRS vs AKA Comparison
KLRS vs AKA Comparison
Compare KLRS & AKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- AKA
- Stock Information
- Founded
- KLRS 2019
- AKA 2018
- Country
- KLRS United States
- AKA United States
- Employees
- KLRS N/A
- AKA N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- AKA Catalog/Specialty Distribution
- Sector
- KLRS Health Care
- AKA Consumer Discretionary
- Exchange
- KLRS Nasdaq
- AKA Nasdaq
- Market Cap
- KLRS 129.0M
- AKA 126.7M
- IPO Year
- KLRS N/A
- AKA 2021
- Fundamental
- Price
- KLRS $2.40
- AKA $11.20
- Analyst Decision
- KLRS Buy
- AKA Buy
- Analyst Count
- KLRS 1
- AKA 4
- Target Price
- KLRS N/A
- AKA $22.50
- AVG Volume (30 Days)
- KLRS 47.1K
- AKA 7.2K
- Earning Date
- KLRS 08-15-2025
- AKA 08-06-2025
- Dividend Yield
- KLRS N/A
- AKA N/A
- EPS Growth
- KLRS N/A
- AKA N/A
- EPS
- KLRS N/A
- AKA N/A
- Revenue
- KLRS N/A
- AKA $586,514,000.00
- Revenue This Year
- KLRS N/A
- AKA $6.60
- Revenue Next Year
- KLRS N/A
- AKA $4.14
- P/E Ratio
- KLRS N/A
- AKA N/A
- Revenue Growth
- KLRS N/A
- AKA 8.09
- 52 Week Low
- KLRS $2.32
- AKA $7.00
- 52 Week High
- KLRS $24.15
- AKA $32.25
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- AKA 40.06
- Support Level
- KLRS N/A
- AKA $12.32
- Resistance Level
- KLRS N/A
- AKA $12.91
- Average True Range (ATR)
- KLRS 0.00
- AKA 0.68
- MACD
- KLRS 0.00
- AKA -0.36
- Stochastic Oscillator
- KLRS 0.00
- AKA 15.82
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.